Unknown

Dataset Information

0

Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.


ABSTRACT: Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under active clinical investigation in combination with DNA-damaging therapeutics in a wide range of sporadic cancers. In this review, the authors discuss DNA repair mechanisms and PARP as a therapeutic target and summarize an update on clinical trials of available PARP inhibitors and predictive biomarkers for their efficacy.

SUBMITTER: Park SR 

PROVIDER: S-EPMC3600582 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Park Sook Ryun SR   Chen Alice A  

Hematology/oncology clinics of North America 20120601 3


Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under active clinical investigation in combination with DNA-damaging therapeutics in a wide range of sporadic cancers. In this review, the authors disc  ...[more]

Similar Datasets

| S-EPMC8879621 | biostudies-literature
| S-EPMC6059530 | biostudies-literature
| S-EPMC8254740 | biostudies-literature
| S-EPMC5564845 | biostudies-literature
| S-EPMC1165381 | biostudies-other
| S-EPMC6992526 | biostudies-literature
| S-EPMC5315304 | biostudies-literature
| S-EPMC8277645 | biostudies-literature